ASCO Annual Meeting

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Dr. Richard Schilsky, from the University of Chicago, Summarizes the Recent Oncology Drug Shortage.

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial

Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas